EYE103

· EyeBiotech Ltd.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for EYE103, covering 2025-08-12 to 2026-01-06. Get the full timeline:

Most recent: Clinical Trial Update: A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME [Phase 2, Phase 3]